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Abstract
Purpose—Alterations in the RAS and RAF pathway relate to epigenetic and epigenomic
aberrations, and are important in colorectal carcinogenesis. KRAS mutation in metastatic colorectal
cancer predicts resistance to anti-EGFR targeted therapy (cetuximab or panitumumab). However, it
remains uncertain whether KRAS mutation predicts prognosis or clinical outcome of colon cancer
patients independent of anti-EGFR therapy.
Methods—We conducted a study of 508 cases identified among 1264 patients with stage III colon
cancer who enrolled in a randomized adjuvant chemotherapy trial (5-fluorouracil, leucovorin with
or without irinotecan) in 1999–2001 (CALGB 89803). KRAS mutations were detected in 178 tumors
Correspondence to: Shuji Ogino, M.D., Ph.D. Center for Molecular Oncologic Pathology Dana-Farber Cancer Institute Brigham and
Women's Hospital Harvard Medical School 44 Binney St., Room JF-215C, Boston, MA 02115, USA Tel: +1-617-632-3978; Fax:
+1-617-277-9015 shuji_ogino@dfci.harvard.edu.
Disclosure of potential conflicts of interest: J.A.M., consultant for Sanofi-Aventis.
L.B.S.; research funding from Pfizer, Roche, Genentech, Bristol Myers Squibb, Imclone, and Amgen; consultant to Pfizer, Roche,
Genentech, Bristol Myers Squibb, Imclone, Amgen, Genzyme and Genomic Health.
A.B.B.; research funding from Pfizer, Imclone, Bristol Myer Squibb, Amgen, and Sanofi Aventis; scientific advisor for Pfizer, Imclone,
Bristol Myer Squibb, Amgen, and Sanofi Aventis. No other conflicts of interest exist.
NIH Public Access
Author Manuscript
Clin Cancer Res. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:













(35%) by Pyrosequencing. Kaplan-Meier and Cox proportional hazard models assessed the
prognostic significance of KRAS mutation and adjusted for potential confounders including age, sex,
tumor location, tumor/node stage, performance status, adjuvant chemotherapy arm and microsatellite
instability (MSI) status.
Results—Compared to patients with KRAS-wild-type tumors, patients with KRAS-mutated tumors
did not experience any difference in disease-free (DFS), recurrence-free (RFS), or overall survival
(OS). Five-year DFS, RFS and OS (KRAS-mutated vs. KRAS-wild-type patients) were: 62% vs. 63%
(log-rank p=0.89); 64% vs. 66% (p=0.84); and 75% vs. 73% (p=0.56), respectively. The effect of
KRAS mutation on patient survival did not significantly differ according to clinical features,
chemotherapy arm or MSI status, and the effect of adjuvant chemotherapy assignment on outcome
did not differ according to KRAS status.
Conclusions—In this large trial of chemotherapy in stage III colon cancer patients, KRAS
mutational status was not associated with any significant influence on disease-free or overall survival.
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INTRODUCTION
KRAS, one of the first genes found to be mutated in human cancer, encodes a G-protein
downstream of receptor tyrosine kinases, including EGFR (1–3). Population-based studies
have shown that approximately 30–40% of colon cancers harbor mutations in codons 12 and
13 of KRAS (4–6). Retrospective observational studies (7–12) as well as randomized controlled
trials (13–17) have consistently shown that KRAS mutation in stage IV colorectal cancer
confers resistance to anti-EGFR targeted treatment (cetuximab or panitumumab). However,
whether KRAS mutation in colorectal cancer has a prognostic role, independent of anti-EGFR
therapy, has been controversial (18–21). Previous data have not been conclusive, even among
several large studies (4,6,22–26). In addition, whether KRAS mutational status modifies the
effect of irinotecan-based chemotherapy remains uncertain.
We therefore examined the influence of KRAS on cancer recurrence and survival in a large
number (N=508) of stage III colon cancer patients enrolled in a National Cancer Institute
(NCI)-sponsored clinical trial of postoperative adjuvant chemotherapy (27). Within this trial
(CALGB 89803), patients were randomized to either fluorouracil and leucovorin or
fluorouracil, leucovorin, and irinotecan. Moreover, since data on pathologic stage, performance
status, postoperative treatment and follow-up were carefully captured in this trial, the
simultaneous impact of disease characteristics and the use of adjuvant therapy could be
assessed to be controlled for potential confounding.
MATERIALS AND METHODS
Study population
Patients in this study were participants in the NCI-sponsored Cancer and Leukemia Group B
(CALGB) adjuvant therapy trial for stage III colon cancer comparing therapy with the weekly
Roswell Park regimen of 5-fluorouracil and leucovorin (FU/LV) to weekly bolus regimen of
irinotecan, 5-FU, and leucovorin (IFL) (CALGB 89803) (27). Between April 1999 and May
2001, 1,264 patients were enrolled on the treatment trial. Patients in the treatment trial (and
thus this companion study) were eligible if they underwent a complete surgical resection of
the primary tumor within 56 days prior to study entry, and had regional lymph node metastases
(stage III colon cancer) but no evidence of distant metastases. Moreover, patients were required
to have a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0–2
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(ambulatory) (28) and have adequate bone marrow, renal and hepatic function. The current
analysis was limited to 508 patients for whom archived formalin-fixed paraffin-embedded
tumor tissue were available and the KRAS gene was sequenced. All patients signed informed
consent, approved by each site's institutional review board.
We compared baseline characteristics of the patients who were included in this study (with
available KRAS data, N=508) with those who were excluded from this study due to
unavailability of tissue data (N=756). We did not detect any significant or substantial difference
between these two groups in terms of age, sex, body mass index (BMI), tumor location, T stage,
N stage, performance status, bowel perforation, bowel obstruction or treatment arm. In
addition, tumor recurrence or mortality did not substantially differ between these two groups;
multivariate hazard ratios (KRAS data available vs. unavailable) were 1.05 (95% CI, 0.87–1.27)
for disease-free survival; 1.05 (95% CI, 0.86–1.28) for recurrence-free survival; and 1.06 (95%
CI, 0.86–1.32) for overall survival.
Definitions of study endpoints
In this study, the primary endpoint was disease-free survival (DFS), defined as time from the
study enrollment to tumor recurrence, occurrence of a new primary colon tumor, or death from
any cause. In addition, we defined recurrence-free survival (RFS) as the time from the study
enrollment to tumor recurrence or occurrence of a new primary colon tumor. For RFS, patients
who died without known tumor recurrence were censored at last documented evaluation by
treating provider. Finally, overall survival (OS) was defined as the time from the study
enrollment to death from any cause.
DNA extraction from tumor, sequencing of KRAS, and MSI analysis
DNA was extracted from paraffin-embedded tissue of colon cancer as previously described
(29). We marked a tumor area on a hematoxylin and eosin (H&E)-stained slide, and dissected
the tumor area from another tumor tissue section by a sterile needle for subsequent DNA
extraction. PCR and Pyrosequencing spanning KRAS codons 12 and 13 were performed as
previously described (29), and validated against Sanger sequencing method (29). In our
KRAS Pyrosequencing assay, we routinely confirmed the presence of a mutation by two
different sequencing primers and by the creation of frameshifted reading of a mutant sequence
relative to a wild-type sequence in a pyrogram (29). Microsatellite instability (MSI) was
assessed using 10 DNA mononucleotide and dinucleotide microsatellite markers as previously
described (30). Tumors showing instability in at least 40% of the loci tested were classified as
MSI-high. Tumors showing instability in no or less than 40% of the loci were classified as
microsatellite stable (MSS)/MSI-low.
Statistical analyses
The goal of this correlative study was to determine whether tumoral KRAS mutational status
influence clinical outcome of patients with stage III colon cancer. Patient registration and
clinical data collection were managed by the CALGB Statistical Center, and analyses were
conducted collaboratively between the CALGB Statistical Center and Dana-Farber Cancer
Institute. All analyses were based on the study database frozen on March 7, 2008, except for
the tumoral KRAS data. All analyses used SAS version 9.1 (SAS Institute, Cary, NC) and all
p values were two-sided.
In the treatment trial (comparing two chemotherapy regimens), there was no statistical
difference in either disease-free or overall survival between the treatment arms (27). The
Kaplan-Meier method was used to describe the distribution of survival time according to
KRAS status, and the log-rank test was performed. We used stage-matched (or stratified) Cox
proportional hazard models to calculate hazard ratios (HRs) of events according to tumoral
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KRAS status, adjusted for age at study entry (as a continuous variable), gender, baseline body
mass index (BMI; ≥30 vs. <30 kg/m2), baseline performance status (0 vs. 1–2), presence of
bowel perforation or obstruction at time of surgery, treatment arm, tumor location (proximal
vs. distal) and MSI status (high vs. low/MSS). Tumor stage (IIIA, IIIB, IIIC or III unspecified
substage) was used as a matching (stratifying) variable (with the “strata” option in the SAS
“proc phreg” command) to minimize residual confounding. The proportionality of hazards
assumption was satisfied by evaluating time-dependent variables, which were the cross-
product of the KRAS variable and survival time (p=0.10 for disease-free survival; p=0.06 for
recurrence-free survival; p=0.24 for overall survival). Covariates with missing variables
[including BMI (1.2% missing), tumor location (1.0% missing), performance status (0.8%
missing), perforation status (1.8% missing) and MSI status (5.5% missing)] were coded with
separate “missing” indicator variables in adjusted models. We assigned 3 cases (0.6%) with
missing information in obstruction status as “no obstruction”. We confirmed that excluding
cases with missing information in any of the covariates did not substantially alter results (data
not shown). An interaction was assessed by including the cross product of the KRAS variable
and another variable of interest in a multivariate Cox model, and the Wald test was performed:
p values were conservatively interpreted, considering multiple hypothesis testing. To assess
an interaction of KRAS and stage, we dichotomized AJCC stage (IIIA-IIIB, N1 vs. IIIC, N2)
as well as assessed an interaction with T stage (T1–2 vs. T3–4). In addition to obtaining a P
value for interaction, we performed stratified analysis to assess potential differential effect of
KRAS mutation, in which we assessed the effect of KRAS mutation simultaneously in two or
more strata (of a variable of interest) in a single Cox regression model (31,32).
As part of the quality assurance program of the CALGB, members of the Audit Committee
visit all participating institutions at least once every three years to review source documents.
The auditors verify compliance with federal regulations and protocol requirements, including
those pertaining to eligibility, treatment, adverse events, tumor response, and outcome in a
sample of protocols at each institution. Such on-site review of medical records was performed
for a subgroup of 328 patients (26%) of the 1264 patients under this study.
RESULTS
KRAS mutation and clinical outcome in stage III colon cancer
Study participants were drawn from a multi-center study of post-operative adjuvant
chemotherapy in patients with stage III colon cancer who underwent a curative-intent surgical
resection. We included 508 cases in this study based on availability of tumor tissue for
KRAS sequencing, which detected a KRAS mutation in 178 (35%) patients. Identified KRAS
mutations were as follows: 56 cases with codon 12 GGT>GAT (p.G12D, c.35G>A); 52 with
codon 13 GGC>GAC (p.G13D, c.38G>A); 32 with codon 12 GGT>GTT (p.G12V, c.35G>T);
21 with codon 12 GGT>TGT (p.G12C, c.34G>T); 9 with codon 12 GGT>GCT (p.G12A, c.
35G>C); 8 with codon 12 GGT>AGT (p.G12S, c.34G>A). Table 1 summarizes baseline
characteristics of study subjects according to KRAS mutational status. Patients with a mutation
in KRAS were significantly less likely to possess microsatellite instability (MSI) or receive
irinotecan, 5-fluorouracil, and leucovorin (IFL) as compared to 5-fluorouracil and leucovorin
(FU/LV).
We assessed the influence of KRAS mutational status on clinical outcome in the 508 patients
with stage III colon cancers. With median follow-up of 6.2 years among surviving participants,
there were 196 events for disease-free survival analysis, 180 events for recurrence-free survival
analysis, and 149 events for overall survival analysis. In Kaplan-Meier analysis, there were no
significant differences in survival time distributions between patients with KRAS mutations
and those with wild-type KRAS [log-rank p=0.89 for disease-free survival (DFS, Figure 1);
log-rank p=0.84 for recurrence-free survival (RFS); log-rank p=0.56 for overall survival (OS)].
Ogino et al. Page 4













DFS at 5 years was 62% for KRAS-mutated and 63% for KRAS-wild-type patients. RFS at 5
years was 64% for KRAS-mutated and 66% for KRAS-wild-type patients. Finally, OS at 5 years
was 75% for KRAS-mutated and 73% for KRAS-wild-type patients.
In a univariate Cox regression analysis, when compared to KRAS-wild-type patients, KRAS-
mutated patients did not experience a significant difference in DFS (HR 0.98; 95% CI, 0.73–
1.31), RFS (HR 0.97; 95% CI, 0.71–1.32), or OS (HR 0.90; 95% CI, 0.64–1.27) (Table 2).
These findings persisted in multivariate analysis that adjusted for clinical, pathologic, or
molecular predictors of patient outcome, and no substantial confounding was identified.
KRAS mutation and clinical outcome in strata of treatment arm
We assessed whether the effect of KRAS mutational status on patient outcome was modified
by adjuvant chemotherapy (Table 3). In both treatment arms (FU/LV and IFL), the presence
of a mutation in KRAS was not associated with any significant difference in patient survival.
Moreover, statistical tests for interaction failed to demonstrate any significant interaction
between chemotherapy assignment and KRAS mutational status (P for interaction = 0.64, 0.67
and 0.60 for DFS, RFS and OS, respectively).
Effect of irinotecan on clinical outcome in strata of KRAS status
We also assessed whether the effect of adjuvant chemotherapy arm on patient survival was
modified by KRAS mutational status (Table 4). In both KRAS-wild-type and KRAS-mutated
cases, there were no significant differences in DFS, RFS or OS between the two treatment
arms.
No significant modifying effect on the relation between KRAS and clinical outcome by any
of the other covariates
Finally, we examined whether there was significant modifying effect on the relation between
KRAS mutation and clinical outcome by any of the other covariates (age, gender, body mass
index, baseline performance status, tumor location, T stage, N stage, stage III substage, status
of bowel perforation or obstruction, and MSI status). There was no evidence for significant
effect modification by any of the variables examined (all Pinteraction>0.23).
DISCUSSION
In this study of 508 patients with stage III colon cancer treated with surgery and adjuvant
chemotherapy, KRAS mutational status was not associated with any significant influence on
cancer recurrence or death. These results were not materially altered in multivariate analyses
that adjusted for other predictors for patient outcome. Moreover, the effect of KRAS mutation
on patient survival did not significantly differ according to clinical features, chemotherapy arm
or MSI status, and the effect of adjuvant chemotherapy arm did not differ according to
KRAS status. In separate independent cohort studies (6,33), we previously showed that
KRAS mutation was not significantly associated with survival of colon cancer patients in
univariate analysis as well as multivariate analysis that adjusted for tumor stage, microsatellite
instability (MSI), BRAF mutation, and other related molecular features. Thus, together with
our previous data, our current data do not support a substantial prognostic role of KRAS
mutation in colon cancer.
Although KRAS mutation does not appear to be a significant prognostic marker in colon cancer,
its importance in colorectal carcinogenesis has been well documented. KRAS is one of the most
commonly mutated oncogenes in human colon cancer. KRAS mutation activates the RAS-RAF
pathway as well as the PI3K-AKT pathway, leading to cellular growth and proliferation (2).
Indeed, KRAS and PIK3CA mutations are associated with each other in colorectal cancer (34,
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35), and KRAS and PIK3CA mutations appear to interact in survival analysis (33). Recently, a
link between KRAS mutation and epigenomic aberrations in colorectal cancer has been
suggested (31,36–38). Specifically, KRAS mutation has been associated with low-level CpG
island methylator phenotype (CIMP-low) (31,36,38,39), and this relation has been shown in
another independent dataset (22). In contrast to somatic mutations including those in KRAS,
epigenomic aberrations are potentially reversible. Although a mechanistic link between
epigenomics and KRAS mutation remains uncertain, analysis of KRAS mutation in colon cancer
may shed lights on epigenomic aberrations in cancer and provide targeted therapeutic
opportunities.
Studying patient outcome has been an important area in cancer research. Accumulating
evidence suggests KRAS mutational status is a critical biomarker to predict response or
resistance to anti-EGFR targeted therapy in patients with metastatic colorectal cancer.
Retrospective observational studies (7–12) as well as randomized controlled trials (13–17)
have consistently shown that KRAS mutation in stage IV colorectal cancer confers resistance
to cetuximab or panitumumab treatment. Thus, KRAS mutation testing is rapidly emerging as
a routine clinical test for patients with metastatic colorectal cancers who are potential
candidates for treatment with either cetuximab or panitumumab (1,2,40).
In contrast to anti-EGFR targeted therapy, the role of KRAS mutation in predicting response
to other therapies remains unclear. For example, a couple previous studies have examined
relationship between KRAS mutation and response to bevacizumab, and shown that KRAS
mutation does not predict response or resistance to bevacizumab in colon cancer (25,41).
While the “predictive” role for KRAS mutational testing in defining sensitivity to anti-EGFR
targeted therapy in stage IV colorectal cancer is now widely accepted, the “prognostic” role
for KRAS as an independent predictor of survival in patients with colorectal cancer remains
less conclusive (18–20). Previous meta-analyses (RASCAL and RASCAL II) (42,43) showed
that KRAS mutation was associated with worse outcome in colorectal cancer. However, these
meta-analyses substantially suffered from publication bias; especially most studies used were
relatively small (N<150 in most studies; N<290 in all included studies). Compared to small
studies with significant results, small studies with null results were more likely unpublished,
and thus more likely excluded from these meta-analyses. Larger studies (e.g., N>290) have
tended to show no independent prognostic significance of KRAS mutation in colorectal cancer.
A large population-based study of 569 colorectal cancer patients reported that KRAS mutation
was independently associated with worse survival (22), while most other large studies found
no independent prognostic role of KRAS mutation (4,6,23–25,44), including a recent study on
1379 stage II-III colon cancers (26). Our current findings were limited to only stage III colon
cancers. Nonetheless, our results were consistent with most previous large studies on colon
cancers including stage III and other stages (4,6,23–26,44). Moreover, although one small
study of 35 patients suggested that KRAS mutational status influenced irinotecan sensitivity
(45), KRAS mutational status did not appear to modify the influence of irinotecan-based
adjuvant therapy in our trial.
There are several advantages in examining associations of molecular markers with outcome
of patients in a NCI-sponsored clinical trial of adjuvant chemotherapy. All patients had stage
III colon cancer, reducing the impact of heterogeneity by disease stage. Moreover, treatment
and follow-up care were all standardized within the clinical trial, and the date and nature of
recurrence were prospectively recorded. In addition, detailed information on other prognostic
variables was routinely collected at study entry.
We recognize that patients who enroll in randomized trials may differ from the population-at-
large. To participate, patients must meet eligibility criteria, be selected as an appropriate
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candidate, and be motivated to participate. In addition, patients were particularly selected for
this study on the basis of availability of colon cancer tissue specimens. Nonetheless,
demographic data of the patients in this study did not suggest significant selection bias.
Moreover, because the study included patients from both community and academic centers
across North America, our findings should reflect the general population of stage III patients
in North America. In addition, although data on KRAS mutational status was available on a
subset of patients enrolled in the trial, baseline characteristics and patient survival did not differ
for patients with and without available archived tumor tissue in this trial.
In conclusion, we found that KRAS mutational status did not significantly predict clinical
outcome in this study of stage III colon cancer patients. Although KRAS mutational testing
should be routinely utilized to assess for appropriate use of anti-EGFR therapy in advanced
colorectal cancer, KRAS status is unlikely to meaningfully predict patient prognosis.
Statement of Translational Relevance
Activating mutations in the KRAS gene are important events during colorectal carcinogenic
process, and predict resistance to anti-EGFR treatment for metastatic colorectal cancer.
However, the literature data on prognostic significance of KRAS mutation in colon cancer
have been conflicting. We have utilized the database of 508 stage III colon cancers in this
adjuvant chemotherapy trial following surgical resection. Since data on pathologic stage,
performance status, post-operative treatment and follow-up were carefully captured in this
trial, the simultaneous impact of disease characteristics and the use of adjuvant therapy
could be assessed to be controlled for potential confounding. We have found that KRAS
mutation does not have a substantial prognostic or predictive role in stage III colon cancer
treated with adjuvant chemotherapy.
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Kaplan-Meier survival curves for disease-free survival (left panel) and overall survival (right
panel) in stage III colon cancer according to KRAS mutational status.
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Table 1
Baseline characteristics according to KRAS mutational status in stage III colon cancer
Clinical or molecular feature No. of cases KRAS
Wild-type Mutant
Total N 508 330 178
Sex
 Male 276 (54%) 179 (54%) 97 (54%)
 Female 232 (46%) 151 (46%) 81 (46%)
Age (years)
 <50 100 (20%) 62 (19%) 38 (21%)
 50–59 130 (26%) 82 (25%) 48 (27%)
 60–69 158 (31%) 102 (31%) 56 (31%)
 >70 120 (24%) 84 (25%) 36 (20%)
 Mean age ± SD 59.8 ± 11.5 60.2 ± 11.6 59.1 ± 11.4
Body mass index (BMI; kg/m2)
 <25 163 (32%) 110 (34%) 53 (30%)
 25–29 182 (36%) 114 (35%) 68 (39%)
 >30 157 (31%) 104 (32%) 53 (30%)
Tumor location
 Right (cecum to transverse colon) 291 (58%) 191 (58%) 100 (57%)
 Left colon (splenic flexure to sigmoid) 212 (42%) 136 (42%) 76 (43%)
T stage
 T1–T2 59 (12%) 43 (13%) 16 (9.1%)
 T3 410 (82%) 260 (80%) 150 (85%)
 T4 33 (6.6%) 23 (7.1%) 10 (5.7%)
N stage
 N1 321 (64%) 203 (62%) 118 (67%)
 N2 184 (36%) 125 (38%) 59 (33%)
AJCC tumor stage
 IIIA 49 (9.7%) 34 (10%) 15 (8.4%)
 IIIB 270 (53%) 167 (51%) 103 (58%)
 IIIC 184 (36%) 125 (38%) 59 (33%)
 III, unknown substage 5 (1.0%) 4 (1.2%) 1 (0.6%)
Performance status score
 0 384 (76%) 246 (75%) 138 (78%)
 1–2 120 (24%) 82 (25%) 38 (22%)
Clinical bowel perforation
 (−) 477 (96%) 310(96%) 167 (95%)
 (+) 22 (4.4%) 14 (4.3%) 8 (4.6%)
Clinical bowel obstruction
 (−) 393 (78%) 252 (77%) 141 (80%)
 (+) 112(22%) 76 (23%) 36 (20%)
MSI status*
 MSS/MSI-low 394 (82%) 247 (78%) 147 (89%)
 MSI-high 86 (18%) 68 (22%) 18 (11%)
Treatment arm*
 FU/LV 266 (52%) 157 (48%) 109 (61%)
 IFL 242 (48%) 173 (52%) 69 (39%)
(%) indicates the proportion of tumors with a specific clinical feature in KRAS-wild-type tumors (or KRAS-mutated tumors). There were cases with missing
value/status for some of the variables.
FU/LV, 5-fluorouracil and leucovorin; IFL, irinotecan, 5-fluorouracil and leucovorin; MSI, microsatellite instability; MSS, microsatellite stable; SD,
standard deviation.
*
Distributional differences are significant with p<0.01.
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